HC Wainwright Cuts Shattuck Labs (NASDAQ:STTK) Price Target to $14.00

Shattuck Labs (NASDAQ:STTK) had its target price trimmed by HC Wainwright from $18.00 to $14.00 in a report released on Tuesday morning, Marketbeat.com reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Shattuck Labs’ Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.52) EPS.

Other analysts have also recently issued reports about the company. Needham & Company LLC boosted their price objective on Shattuck Labs from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, June 8th. Citigroup raised shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Friday, June 5th. Cantor Fitzgerald assumed coverage on shares of Shattuck Labs in a research report on Monday, April 27th. They set an “overweight” rating for the company. Weiss Ratings upgraded shares of Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Finally, Wall Street Zen upgraded shares of Shattuck Labs from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Shattuck Labs presently has an average rating of “Moderate Buy” and an average price target of $12.12.

Shattuck Labs Stock Performance

NASDAQ STTK opened at $7.32 on Tuesday. The stock has a market capitalization of $561.30 million, a P/E ratio of -14.35 and a beta of 1.08. Shattuck Labs has a 52 week low of $0.79 and a 52 week high of $8.33. The stock has a fifty day moving average of $6.37 and a 200-day moving average of $5.94.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). Equities research analysts forecast that Shattuck Labs will post -0.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Shattuck Labs

In other news, insider Abhinav A. Shukla sold 23,365 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $7.08, for a total transaction of $165,424.20. Following the completion of the transaction, the insider directly owned 86,380 shares in the company, valued at approximately $611,570.40. The trade was a 21.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Clay B. Siegall purchased 62,500 shares of the stock in a transaction dated Tuesday, June 9th. The stock was bought at an average cost of $4.00 per share, with a total value of $250,000.00. Following the completion of the purchase, the director owned 318,608 shares in the company, valued at $1,274,432. The trade was a 24.40% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have sold 53,875 shares of company stock valued at $379,305. 8.79% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Orbimed Advisors LLC bought a new stake in Shattuck Labs in the third quarter valued at approximately $15,072,000. BlackRock Inc. acquired a new stake in Shattuck Labs in the second quarter worth $27,315,000. NEXTBio Capital Management LP bought a new position in shares of Shattuck Labs during the fourth quarter worth $11,497,000. Price T Rowe Associates Inc. MD bought a new position in shares of Shattuck Labs during the fourth quarter worth $7,031,000. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Shattuck Labs in the 4th quarter valued at $4,945,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.